Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Q3 2025 value amounting to $473000.0.

  • Rocket Pharmaceuticals' Interest Expenses rose 42.46% to $473000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 42.49%. This contributed to the annual value of $1.9 million for FY2024, which is 58.67% up from last year.
  • Rocket Pharmaceuticals' Interest Expenses amounted to $473000.0 in Q3 2025, which was up 42.46% from $473000.0 recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Interest Expenses peaked at $1.7 million during Q1 2021, and registered a low of $251000.0 during Q2 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Interest Expenses had a median value of $470000.0 in 2023 and averaged $527210.5.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Interest Expenses crashed by 8594.62% in 2021, and later skyrocketed by 8525.9% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Interest Expenses (Quarter) stood at $463000.0 in 2021, then increased by 0.86% to $467000.0 in 2022, then rose by 0.64% to $470000.0 in 2023, then increased by 0.64% to $473000.0 in 2024, then changed by 0.0% to $473000.0 in 2025.
  • Its last three reported values are $473000.0 in Q3 2025, $473000.0 for Q2 2025, and $472000.0 during Q1 2025.